Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1351 to 1365 of 2011 results for nice guidelines

  1. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

  2. Zio XT for detecting cardiac arrhythmias (HTG562)

    Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.

  3. What is the optimal antibiotic prophylaxis regimen for women who are having a surgical abortion?

    review the evidence this. A cross-reference has been included to the NICE guideline on preventing sexually transmitted...

  4. What clinical features and laboratory investigations can be used to better stratify risk for women in labour with signs of sepsis (including fever and tachycardia)?

    measurement of pulse, blood pressure and respiratory rate in line with the NICE guideline on sepsis . Hourly monitoring of...

  5. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

  6. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  7. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

  8. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation.

  9. Digital technologies to support self-management of asthma: early-use assessment (HTG778)

    Evidence-based recommendations on the early use of digital technologies to support self-management of asthma.

  10. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

  11. NaviCam for diagnosing gastrointestinal tract conditions (MIB104)

    NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .

  12. Antimicrobial prescribing: meropenem with vaborbactam (ES21)

    Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making

  13. Temperature control to improve neurological outcomes after cardiac arrest (HTG710)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

  14. HemaClear for bloodless surgical field during limb surgery (MIB187)

    NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .

  15. InterDry for intertrigo (MIB192)

    NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .